These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 14661365

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Evolution of the therapeutic drug monitoring of cyclosporine.
    Citterio F.
    Transplant Proc; 2004 Mar; 36(2 Suppl):420S-425S. PubMed ID: 15041378
    [Abstract] [Full Text] [Related]

  • 4. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
    Shenoy S, Hardinger KL, Crippin J, Korenblat K, Lisker-Melman M, Lowell JA, Chapman W.
    Liver Transpl; 2008 Feb; 14(2):173-80. PubMed ID: 18236391
    [Abstract] [Full Text] [Related]

  • 5. Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients.
    Schubert S, Abdul-Khaliq H, Lehmkuhl HB, Hübler M, Abd El Rahman MY, Miera O, Ewert P, Weng Y, Wei H, Krüdewagen B, Hetzer R, Berger F.
    J Heart Lung Transplant; 2006 Jun; 25(6):619-25. PubMed ID: 16730566
    [Abstract] [Full Text] [Related]

  • 6. Study of cyclosporine level at 2 hours after administration in preoperative kidney transplant recipients for prediction of postoperative optimal cyclosporine dose.
    Sukhavasharin N, Praditpornsilpa K, Avihingsanon Y, Kuoatawintu P, O-Charoen R, Kansanabuch T, Tungsanga K, Eiam-Ong S.
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S15-20. PubMed ID: 17044449
    [Abstract] [Full Text] [Related]

  • 7. Correlation of C0 and C2 levels with cyclosporine side effects in kidney transplantation.
    Rodrigo E, Ruiz JC, Angeles de Cos M, Ruiz J, Gago M, Piñera C, Sánchez B, González-Cotorruelo J, Gómez-Alamillo C, Arias M.
    Transplant Proc; 2009 Aug; 41(6):2328-31. PubMed ID: 19715910
    [Abstract] [Full Text] [Related]

  • 8. C2 is an age-independent parameter for optimal cyclosporine exposure in long-term kidney transplant recipients.
    Ferraresso M, Citterio F, Ghio L, Romagnoli J, Edefonti A, Berardinelli L, Castagneto M.
    Transplant Proc; 2004 Nov; 36(9):2656-8. PubMed ID: 15621115
    [Abstract] [Full Text] [Related]

  • 9. Enhanced clinical utility of de novo cyclosporine C2 monitoring after lung transplantation.
    Morton JM, Aboyoun CL, Malouf MA, Plit ML, Glanville AR.
    J Heart Lung Transplant; 2004 Sep; 23(9):1035-9. PubMed ID: 15454168
    [Abstract] [Full Text] [Related]

  • 10. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. C2 and C0 values for monitoring cyclosporine therapy in stable heart transplant recipients.
    Diciolla F, Scolletta S, Berti L, Maccherini M, Federici D, Bernazzali S, Lisi G, Chiavarelli M.
    Transplant Proc; 2005 Mar; 37(2):1355-9. PubMed ID: 15848719
    [Abstract] [Full Text] [Related]

  • 13. Calcineurin Inhibitor Determination in Whole Blood With the RXL Dimension Analyzer: A Useful Tool for Immunosuppressive Drug Monitoring.
    Ventura E, Bonardet A, Pageaux GP, Mourad G, Cristol JP.
    Transplant Proc; 2009 Mar; 41(2):707-9. PubMed ID: 19328963
    [Abstract] [Full Text] [Related]

  • 14. Therapeutic monitoring of cyclosporine in kidney transplantation: the Halifax experience.
    Singh D, Kiberd B, Belitsky P, Fraser A, Balbontin F, Lawen J.
    Transplant Proc; 2004 Mar; 36(2 Suppl):414S-419S. PubMed ID: 15041377
    [Abstract] [Full Text] [Related]

  • 15. Therapeutic drug monitoring of cyclosporine.
    Midtvedt K.
    Transplant Proc; 2004 Mar; 36(2 Suppl):430S-433S. PubMed ID: 15041380
    [Abstract] [Full Text] [Related]

  • 16. Cyclosporine C2 monitoring improves renal dysfunction after lung transplantation.
    Glanville AR, Morton JM, Aboyoun CL, Plit ML, Malouf MA.
    J Heart Lung Transplant; 2004 Oct; 23(10):1170-4. PubMed ID: 15477111
    [Abstract] [Full Text] [Related]

  • 17. Graft function based on two hours peak level monitoring of cyclosporine A during the first six months of renal transplantation.
    Hami M, Naghibi M, Mojahedi MJ, Sharifipour F, Shakeri MT.
    Saudi J Kidney Dis Transpl; 2012 Nov; 23(6):1169-74. PubMed ID: 23168844
    [Abstract] [Full Text] [Related]

  • 18. Early cyclosporine C0 and C2 monitoring in de novo kidney transplant patients: a prospective randomized single-center pilot study.
    Kyllönen LE, Salmela KT.
    Transplantation; 2006 Apr 15; 81(7):1010-5. PubMed ID: 16612277
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Impact of late conversion from C0 to C2 monitoring of microemulsified cyclosporine in pediatric living donor liver transplant recipients.
    Takatsuki M, Chen CL, Chen YS, Wang CC, Lin CC, Yang CH, Yong CC, Liu YW.
    Clin Transplant; 2004 Dec 15; 18(6):694-9. PubMed ID: 15516246
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.